Network Version
Evatanepag Data Sheet
| Product Name: | Evatanepag |
 |
|---|---|---|
| CAS No.: | 223488-57-1 | |
| Cat. No.: | HY-14839 | |
| MWt: | 468.57 | |
| Formula: | C25H28N2O5S | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 32 mg/mL | |
| Mechanisms: | Target: Cardiovascular Disease Endocrinology Inflammation/Immunology | |
| Biological Activity: | ||
|
Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma[1][2].
In Vitro: Evatanepag (10 nM, 30 min) inhibits hFcεRI-induced mast cells degranulation in a dose-dependent manner[2]. Evatanepag (0.1 nM-10 μM, 12 min) results in an equivalent increase in intracellular cAMP in HEK-293 cells, with an IC50 of 50 nM[3]. In Vivo: Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats[1]. Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice[2]. Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t1/2: 0.33 h)[1]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com